Bioorganic and Medicinal Chemistry Letters

, том 22 , издание 1 , страницы 262-266

Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases

Patrick A Plé ¹

Frédéric Jung ¹

Sue Ashton ²

Laurent Hennequin ¹

Romuald Laine ²

Rémy Morgentin ¹

Georges Pasquet ¹

SIAN TAYLOR ²

Скрыть аффилиации авторов Показать аффилиации авторов: 2 аффилиации

AstraZeneca, Centre de Recherches, B.P. 1050, 51689 Reims Cedex 2, France. |

AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. |

Тип публикации: Journal Article

Дата публикации: 2012-01-01

Elsevier

Bioorganic and Medicinal Chemistry Letters

scimago Q2

wos Q2

БС2

SJR: 0.472

CiteScore: 5.1

Impact factor: 2.2

ISSN: 0960894X, 14643405

DOI: 10.1016/j.bmcl.2011.11.019

Скопировать DOI

PubMed ID: 22153662

Organic Chemistry

Drug Discovery

Biochemistry

Molecular Biology

Pharmaceutical Science

Clinical Biochemistry

Molecular Medicine

Краткое описание

AZD2932 . A new series of Quinazoline Ether Inhibitor which potently inhibits VEGFR-2 and PDGFR tyrosine kinases is described here. In vitro, pharmacokinetics and in vivo evaluations led to the selection of AZD2932 .

Найдено

1 цитирование

Эльгазар Абдулла

🥼 🤝

33 публикации, 657 цитирований, 2 рецензии

Индекс Хирша: 18

Университет Кафр-эш-Шейха

Топ-30

Журналы

	1 2 3 4 5
Bioorganic Chemistry	Bioorganic Chemistry, 5, 11.9% Bioorganic Chemistry 5 публикаций, 11.9%
European Journal of Medicinal Chemistry	European Journal of Medicinal Chemistry, 3, 7.14% European Journal of Medicinal Chemistry 3 публикации, 7.14%
Journal of Medicinal Chemistry	Journal of Medicinal Chemistry, 3, 7.14% Journal of Medicinal Chemistry 3 публикации, 7.14%
RSC Advances	RSC Advances, 3, 7.14% RSC Advances 3 публикации, 7.14%
Molecules	Molecules, 2, 4.76% Molecules 2 публикации, 4.76%
Bioorganic and Medicinal Chemistry Letters	Bioorganic and Medicinal Chemistry Letters, 2, 4.76% Bioorganic and Medicinal Chemistry Letters 2 публикации, 4.76%
Journal of Enzyme Inhibition and Medicinal Chemistry	Journal of Enzyme Inhibition and Medicinal Chemistry, 2, 4.76% Journal of Enzyme Inhibition and Medicinal Chemistry 2 публикации, 4.76%
Future Medicinal Chemistry	Future Medicinal Chemistry, 2, 4.76% Future Medicinal Chemistry 2 публикации, 4.76%
IET Nanobiotechnology	IET Nanobiotechnology, 1, 2.38% IET Nanobiotechnology 1 публикация, 2.38%
Toxicologic Pathology	Toxicologic Pathology, 1, 2.38% Toxicologic Pathology 1 публикация, 2.38%
Tumor Biology	Tumor Biology, 1, 2.38% Tumor Biology 1 публикация, 2.38%
BMC Chemistry	BMC Chemistry, 1, 2.38% BMC Chemistry 1 публикация, 2.38%
Heliyon	Heliyon, 1, 2.38% Heliyon 1 публикация, 2.38%
Chemical Biology and Drug Design	Chemical Biology and Drug Design, 1, 2.38% Chemical Biology and Drug Design 1 публикация, 2.38%
Journal of Heterocyclic Chemistry	Journal of Heterocyclic Chemistry, 1, 2.38% Journal of Heterocyclic Chemistry 1 публикация, 2.38%
ChemMedChem	ChemMedChem, 1, 2.38% ChemMedChem 1 публикация, 2.38%
Archiv der Pharmazie	Archiv der Pharmazie, 1, 2.38% Archiv der Pharmazie 1 публикация, 2.38%
ChemInform	ChemInform, 1, 2.38% ChemInform 1 публикация, 2.38%
Organic and Biomolecular Chemistry	Organic and Biomolecular Chemistry, 1, 2.38% Organic and Biomolecular Chemistry 1 публикация, 2.38%
Russian Journal of General Chemistry	Russian Journal of General Chemistry, 1, 2.38% Russian Journal of General Chemistry 1 публикация, 2.38%
Expert Opinion on Therapeutic Patents	Expert Opinion on Therapeutic Patents, 1, 2.38% Expert Opinion on Therapeutic Patents 1 публикация, 2.38%
Journal of Biomolecular Structure and Dynamics	Journal of Biomolecular Structure and Dynamics, 1, 2.38% Journal of Biomolecular Structure and Dynamics 1 публикация, 2.38%
Heterocyclic Communications	Heterocyclic Communications, 1, 2.38% Heterocyclic Communications 1 публикация, 2.38%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 1, 2.38% International Journal of Molecular Sciences 1 публикация, 2.38%
Pharmaceutical Fronts	Pharmaceutical Fronts, 1, 2.38% Pharmaceutical Fronts 1 публикация, 2.38%
Bioorganic and Medicinal Chemistry	Bioorganic and Medicinal Chemistry, 1, 2.38% Bioorganic and Medicinal Chemistry 1 публикация, 2.38%
Drug Design, Development and Therapy	Drug Design, Development and Therapy, 1, 2.38% Drug Design, Development and Therapy 1 публикация, 2.38%
Scientific Reports	Scientific Reports, 1, 2.38% Scientific Reports 1 публикация, 2.38%
	1 2 3 4 5

Издатели

	2 4 6 8 10 12
Elsevier	Elsevier, 12, 28.57% Elsevier 12 публикаций, 28.57%
Taylor & Francis	Taylor & Francis, 7, 16.67% Taylor & Francis 7 публикаций, 16.67%
Wiley	Wiley, 5, 11.9% Wiley 5 публикаций, 11.9%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 4, 9.52% Royal Society of Chemistry (RSC) 4 публикации, 9.52%
MDPI	MDPI, 3, 7.14% MDPI 3 публикации, 7.14%
American Chemical Society (ACS)	American Chemical Society (ACS), 3, 7.14% American Chemical Society (ACS) 3 публикации, 7.14%
SAGE	SAGE, 2, 4.76% SAGE 2 публикации, 4.76%
Springer Nature	Springer Nature, 2, 4.76% Springer Nature 2 публикации, 4.76%
Institution of Engineering and Technology (IET)	Institution of Engineering and Technology (IET), 1, 2.38% Institution of Engineering and Technology (IET) 1 публикация, 2.38%
Pleiades Publishing	Pleiades Publishing, 1, 2.38% Pleiades Publishing 1 публикация, 2.38%
Walter de Gruyter	Walter de Gruyter, 1, 2.38% Walter de Gruyter 1 публикация, 2.38%
Georg Thieme Verlag KG	Georg Thieme Verlag KG, 1, 2.38% Georg Thieme Verlag KG 1 публикация, 2.38%
	2 4 6 8 10 12

Мы не учитываем публикации, у которых нет DOI.
Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.

Войти с ORCID

Метрики

Цитировать

ГОСТ |

Цитировать

ГОСТ Скопировать

Plé P. A. et al. Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases // Bioorganic and Medicinal Chemistry Letters. 2012. Vol. 22. No. 1. pp. 262-266.

ГОСТ со всеми авторами (до 50) Скопировать

Plé P. A., Jung F., Ashton S., Hennequin L., Laine R., Morgentin R., Pasquet G., TAYLOR S. Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases // Bioorganic and Medicinal Chemistry Letters. 2012. Vol. 22. No. 1. pp. 262-266.

RIS |

Цитировать

RIS Скопировать

TY - JOUR

DO - 10.1016/j.bmcl.2011.11.019

UR - https://doi.org/10.1016/j.bmcl.2011.11.019

TI - Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases

T2 - Bioorganic and Medicinal Chemistry Letters

AU - Plé, Patrick A

AU - Jung, Frédéric

AU - Ashton, Sue

AU - Hennequin, Laurent

AU - Laine, Romuald

AU - Morgentin, Rémy

AU - Pasquet, Georges

AU - TAYLOR, SIAN

PY - 2012

DA - 2012/01/01

PB - Elsevier

SP - 262-266

IS - 1

VL - 22

PMID - 22153662

SN - 0960-894X

SN - 1464-3405

ER -

BibTex |

Цитировать

BibTex (до 50 авторов) Скопировать

@article{2012_Plé,

author = {Patrick A Plé and Frédéric Jung and Sue Ashton and Laurent Hennequin and Romuald Laine and Rémy Morgentin and Georges Pasquet and SIAN TAYLOR},

title = {Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases},

journal = {Bioorganic and Medicinal Chemistry Letters},

year = {2012},

volume = {22},

publisher = {Elsevier},

month = {jan},

url = {https://doi.org/10.1016/j.bmcl.2011.11.019},

number = {1},

pages = {262--266},

doi = {10.1016/j.bmcl.2011.11.019}

}

MLA

Цитировать

MLA Скопировать

Plé, Patrick A., et al. “Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases.” Bioorganic and Medicinal Chemistry Letters, vol. 22, no. 1, Jan. 2012, pp. 262-266. https://doi.org/10.1016/j.bmcl.2011.11.019.

Издатель

Elsevier

Журнал

Bioorganic and Medicinal Chemistry Letters

scimago Q2

wos Q2

БС2

SJR

0.472

CiteScore

5.1

Impact factor

2.2

ISSN

0960894X (Print)

14643405 (Electronic)